Latest Breaking News On - Patients with relapsed refractoryb cell malignancies - Page 1 : comparemela.com

The novel BTK degrader BGB-16673 was well tolerated; produced meaningful and rapid clinical responses; and demonstrated on-target effects in patients with relapsed/refractory B-cell malignancies.

Johnf seymourClinical research at peter maccallum cancer centreClinical researchPeter maccallum cancer centreBgb 16673 101 studyBtk degrader bgb 16673Patients with relapsed refractoryb cell malignancies